- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Facing pharmacy trends for the remainder of the year
- State of the market: Are generic drugs approaching their peak?
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Americans more likely than others to prefer generics, study finds
PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.
The India-based generic drug maker announced the launch of cevimeline hydrochloride in the 30-mg strength under an agreement with parent company Daiichi Sankyo. The drug is used in patients with Sjogren's syndrome, which affects the moisture-producing glands.
Daiichi Sankyo markets the drug under the name Evoxac. The drug had sales of $62.4 million during the 12-month period ended in June 2011, according to IMS Health.
An authorized generic is a branded drug marketed under its generic name at a lowered price. Apotex is marketing the generic version of the drug.